MX2012005155A - Compuestos de quinazolina. - Google Patents

Compuestos de quinazolina.

Info

Publication number
MX2012005155A
MX2012005155A MX2012005155A MX2012005155A MX2012005155A MX 2012005155 A MX2012005155 A MX 2012005155A MX 2012005155 A MX2012005155 A MX 2012005155A MX 2012005155 A MX2012005155 A MX 2012005155A MX 2012005155 A MX2012005155 A MX 2012005155A
Authority
MX
Mexico
Prior art keywords
quinazoline compounds
compounds
quinazoline
formula
disclosed
Prior art date
Application number
MX2012005155A
Other languages
English (en)
Inventor
Joanne Philp
Lara S Kallander
Brian Griffin Lawhorn
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of MX2012005155A publication Critical patent/MX2012005155A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describen compuestos que tienen la fórmula (ver formula). en donde R1, R2, R3, R4, R5, R6 y R7 son como se definen en la presente, y métodos para hacer y utilizar los mismos.
MX2012005155A 2009-11-03 2010-11-01 Compuestos de quinazolina. MX2012005155A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25764609P 2009-11-03 2009-11-03
PCT/US2010/054927 WO2011056740A1 (en) 2009-11-03 2010-11-01 Quinazoline compounds

Publications (1)

Publication Number Publication Date
MX2012005155A true MX2012005155A (es) 2012-08-31

Family

ID=43970282

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012005155A MX2012005155A (es) 2009-11-03 2010-11-01 Compuestos de quinazolina.

Country Status (13)

Country Link
US (1) US8859571B2 (es)
EP (1) EP2501233B1 (es)
JP (1) JP5836963B2 (es)
KR (1) KR101736521B1 (es)
CN (1) CN102711474B (es)
AU (1) AU2010315361B2 (es)
BR (1) BR112012010524A2 (es)
CA (1) CA2779989A1 (es)
EA (1) EA021439B1 (es)
ES (1) ES2523465T3 (es)
IL (1) IL219504A (es)
MX (1) MX2012005155A (es)
WO (1) WO2011056740A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010094695A1 (en) * 2009-02-17 2010-08-26 Boehringer Ingelheim International Gmbh Pyrimido [5,4-d] pyrimidine derivatives for the inhibition of tyrosine kinases
CN103159685A (zh) * 2013-04-11 2013-06-19 苏州立新制药有限公司 4-氯-6，7-二(2-甲氧基乙氧基)喹唑啉的制备方法
EP3071204B1 (en) * 2013-11-20 2019-02-20 SignalChem Lifesciences Corp. Quinazoline derivatives as tam family kinase inhibitors
JP6386562B2 (ja) 2013-12-26 2018-09-05 エクソンモービル リサーチ アンド エンジニアリング カンパニーＥｘｘｏｎ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｅｎｇｉｎｅｅｒｉｎｇ Ｃｏｍｐａｎｙ Ｚｓｍ−４８結晶の合成
CA3081548A1 (en) * 2017-09-26 2019-04-04 The Regents Of The University Of California Compositions and methods for treating cancer
CN114521196A (zh) 2019-09-16 2022-05-20 诺华股份有限公司 双官能团降解剂及其使用方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9508565D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
ES2925655T3 (es) 2003-09-26 2022-10-19 Exelixis Inc Moduladores c-Met y métodos de uso
NZ592990A (en) 2005-11-01 2013-01-25 Targegen Inc Bi-aryl meta-pyrimidine inhibitors of kinases

Also Published As

Publication number Publication date
WO2011056740A1 (en) 2011-05-12
US20120220588A1 (en) 2012-08-30
IL219504A (en) 2016-09-29
CN102711474B (zh) 2014-09-10
KR20120112441A (ko) 2012-10-11
BR112012010524A2 (pt) 2017-12-12
CN102711474A (zh) 2012-10-03
EP2501233B1 (en) 2014-09-24
AU2010315361B2 (en) 2014-06-12
ES2523465T3 (es) 2014-11-26
KR101736521B1 (ko) 2017-05-16
JP2013510155A (ja) 2013-03-21
EA021439B1 (ru) 2015-06-30
EP2501233A1 (en) 2012-09-26
CA2779989A1 (en) 2011-05-12
EA201290243A1 (ru) 2012-12-28
EP2501233A4 (en) 2013-06-19
IL219504A0 (en) 2012-06-28
AU2010315361A1 (en) 2012-05-24
US8859571B2 (en) 2014-10-14
JP5836963B2 (ja) 2015-12-24

Similar Documents

Publication Publication Date Title
MX341133B (es) Compuestos y metodos para la inhibición de hdac.
MX2012008141A (es) Compuestos y metodos.
MY169043A (en) New dihydroquinoline-2-one derivatives
MX341456B (es) Amino-quinolinas como inhibidores de cinasa.
PH12014502697B1 (en) New diazaspirocycloalkane and azaspirocycloalkane
MX341825B (es) Compuestos de heteroarilo y usos de los mismos.
EP2566477A4 (en) AMINO-QUINOLINES AS KINASE INHIBITORS
IN2015DN00960A (es)
MX2014001879A (es) Aminoquinazolinas como inhibidores de quinasa.
MY165238A (en) Substituted pyrrolidine-2-carboxamides
MY160424A (en) Substituted pyrrolidine-2-carboxyamides.
MY181898A (en) Heterocyclic compounds and uses thereof
PH12014501179B1 (en) New bicyclic dihydroisoquinoline-1-one derivatives
TN2011000673A1 (en) Bace inhibitors
MX2014014531A (es) Derivados de aminoquinazolina y piridopirimidina.
EA201170154A1 (ru) Производные пиридинопиридинонов, способ их получения и применение в терапии
PH12015500345A1 (en) Amino-quinolines as kinase inhibitors
MY169267A (en) New aryl-quinoline derivatives
PH12015500363A1 (en) Prodrugs of amino quinazoline kinase inhibitor
NZ597483A (en) N1-substituted-5-fluoro-2-oxopyrimidinone-1(2h)-carboxamide derivatives
MX2012005155A (es) Compuestos de quinazolina.
PH12015500399A1 (en) Azaindolines
MX2012014796A (es) Proceso para preparar 4-hidroxipiridinas.
MX344429B (es) Nuevos compuestos de hexahidropirroloimidazolona.
IN2013MN01107A (es)

Legal Events

Date Code Title Description
FG Grant or registration